Iveric bio (ISEE): APLS Data As Good As Possible for Iveric, Buy Here - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- European shares subdued as surging crude sharpens focus on ECB rate path
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Iveric Bio (ISEE) PT Raised to $21 at Wedbush
September 10, 2021 7:41 AM EDTWedbush analyst David Nierengarten raised the price target on Iveric Bio (NASDAQ: ISEE) to $21.00 (from $16.00) while maintaining an Outperform rating.
"In our opinion the Phase 3 results announced by APLS (Neutral, Laura Chico) represent a best-case scenario for ISEE shares," the analyst commented.
... MoreIveric Bio (ISEE) PT Raised to $25 at Cowen; APLS Data Disclosure 'As Good As Possible for Iveric'
September 10, 2021 6:48 AM EDTCowen analyst Ken Cacciatore raised the price target on Iveric Bio (NASDAQ: ISEE) to $25.00 (from $15.00) while maintaining an Outperform rating, saying the data from competitor APLS is as good as possible for the company.
The analyst commented, "The APLS results could not... More
Iveric Bio (ISEE) PT Raised to $18 at Credit Suisse
September 10, 2021 6:09 AM EDTCredit Suisse analyst Tiago Fauth raised the price target on Iveric Bio (NASDAQ: ISEE) to $18.00 (from $15.00) while maintaining a Outperform rating.... More
Stifel Starts Iveric Bio (ISEE) at Buy
September 10, 2021 1:59 AM EDTStifel analyst Annabel Samimy initiates coverage on Iveric Bio (NASDAQ: ISEE) with a Buy rating and a price target of $22.00.
The analyst comments "We are initiating coverage of IVERIC bio (ISEE) with a Buy rating and a 12-month target price of... More
After-Hours Stock Movers 09/09: (ISEE) (AFRM) (KPLT) Higher; (APLS) (COOK) (ZUMZ) Lower (more...)
September 9, 2021 5:52 PM EDTAfter-Hours Stock Movers:
IVERIC bio (NASDAQ: ISEE) 41.4% HIGHER; gains following data from Apellis
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) 30.8% LOWER; reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively,... More
UPDATE: IVERIC bio (ISEE) Gains Following Results From Apellis Pharmaceuticals (APLS)
September 9, 2021 4:14 PM EDT(Updated - September 9, 2021 4:22 PM EDT)
IVERIC bio (NASDAQ: ISEE) Strength Post-Market Said Tied to Results from Apellis Pharmaceuticals (NASDAQ: APLS)
Shares Up 17%Update:
Shares Are Now Up 22%Catalyst Biosciences (NASDAQ: CBIO) Also Gained, up 15%... More